AIM Stock Catalyst: AIM ImmunoTech Announces 50% Objective Response Rate in Phase 2 Trial of Ampligen

AIM ImmunoTech Inc. (NYSE: AIM) announced the final primary endpoint report on objective response rate data from its Phase 2 trial evaluating Ampligen. The topline results indicate a 50% objective response rate, including 21% complete responses.

The trial assessed the efficacy of Ampligen in the treatment of a specific condition. The reported objective response rate of 50% and complete response rate of 21% are based on the trial's primary endpoint.

As of the latest data, AIM ImmunoTech has a free float of 2,777,828 shares and 8,147,782 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.